Is Vertex’s New CF Drug Unprecedented? Incremental? Expensive? Maybe All Three – Forbes

Posted: March 31, 2017 at 7:16 am


Forbes
Is Vertex's New CF Drug Unprecedented? Incremental? Expensive? Maybe All Three
Forbes
Shares in Boston's Vertex Pharmaceuticals are up 22% to $109 after the biotechnology company released data on an experimental combination pill to treat cystic fibrosis, a genetic disease that shortens patients' lives by affecting their lungs and ...
Vertex boosted by strong trial data for next-gen CF drugBioPharma Dive
Vertex CF combo succeeds in late-stage trialsPharmaLive (press release) (subscription)

all 164 news articles »

More here:

Is Vertex's New CF Drug Unprecedented? Incremental? Expensive? Maybe All Three - Forbes

Related Posts